Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration
Junhu Tai, Mun Soo Han, Dabin Lee, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1073-1073
Open Access | Times Cited: 47
Hepatitis B functional cure and immune response
Jia-Rui Zheng, Zilong Wang, Bo Feng
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 32
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis
Riccardo Nevola, Domenico Beccia, Valerio Rosato, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7651-7651
Open Access | Times Cited: 17
Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels
Ruoyao Qi, Rao Fu, Lei Xing, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 714-729
Closed Access | Times Cited: 5
Review article: hepatitis B—current and emerging therapies
David Yardeni, Marc G. Ghany
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 805-819
Closed Access | Times Cited: 22
Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment
Hao Yang, Zili Gu, Zhenfeng Yu, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2724-2724
Open Access | Times Cited: 18
The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus
Ling Ding, Jiaquan Huang, Shuai-Wen Huang
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Julio Aguilar, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 9
Immune therapies against chronic hepatitis B
Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Yoichi Hiasa
Journal of Gastroenterology (2022) Vol. 57, Iss. 8, pp. 517-528
Open Access | Times Cited: 14
The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Aguilar, et al.
Vaccines (2021) Vol. 10, Iss. 1, pp. 45-45
Open Access | Times Cited: 17
Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies
Ankita Singh, Jitendra Kumar, Vijay Kumar
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 18, pp. 1727-1752
Closed Access | Times Cited: 7
Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
Julio Aguilar, Jorge Aguiar, Sheikh Mohammad Fazle Akbar
Vaccines (2022) Vol. 10, Iss. 12, pp. 2087-2087
Open Access | Times Cited: 9
Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
Mamun Al‐Mahtab, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 962-962
Open Access | Times Cited: 4
Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1944-1944
Open Access | Times Cited: 4
Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity
Yan Mu, Xiaohe Ren, Di Han, et al.
Pharmaceutics (2022) Vol. 14, Iss. 7, pp. 1439-1439
Open Access | Times Cited: 7
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
Ruoyao Qi, Jiali Cao, Yangtao Wu, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 3
Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Md. Sakirul Islam Khan, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1644-1644
Open Access | Times Cited: 5
Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Yoichi Hiasa
(2023)
Open Access | Times Cited: 1
Evolution and diversity of the hepatitis B virus genome: Clinical implications
Chengzuo Xie, Daiqiang Lu
Virology (2024) Vol. 598, pp. 110197-110197
Closed Access
Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Md. Sakirul Islam Khan, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 746-746
Open Access | Times Cited: 1
Cloning and Expression of HBcAg Using Food Grade Vector pNZ8149 in Lactococcus Lactis for the Development of HBV Therapeutic Vaccine
Rifqiyah N. Umami, Rahma I. Anwar, Hidayah Murtiyaningsih, et al.
(2023), pp. 833-846
Open Access
Page 1

Scroll to top